Role of Serum Soluble Interleukin-2 Receptor Level in the Diagnosis of Sarcoidosis: A Systematic Review and Meta-Analysis.
Journal
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
ISSN: 2532-179X
Titre abrégé: Sarcoidosis Vasc Diffuse Lung Dis
Pays: Italy
ID NLM: 9610928
Informations de publication
Date de publication:
28 Mar 2023
28 Mar 2023
Historique:
received:
27
07
2022
accepted:
06
02
2023
medline:
29
3
2023
entrez:
28
3
2023
pubmed:
29
3
2023
Statut:
epublish
Résumé
Serum Soluble Interleukin-2 Receptor (sIL-2R) levels are used clinically as a disease activity marker for systemic sarcoidosis. Studies have investigated the diagnostic role of serum soluble interleukin-2 receptor (sIL-2R) level for sarcoidosis relative to biopsy. We performed a systematic review and meta-analysis of studies evaluating the diagnostic utility of sIL-2R. We carried out an electronic search in Medline, Embase, Google Scholar, and Cochrane databases using keyword and Medical Subject Heading (MeSH) terms: sarcoidosis and sIL-2R. Studies evaluating the sIL-2R levels as a diagnostic tool in clinically diagnosed or biopsy-proven sarcoidosis patients compared to control groups with non-sarcoidosis patients were included. Forest plots were constructed using a random effect model depicting pooled sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy. We selected ten studies comprising 1477 patients, with 592 in the sarcoidosis group and 885 in the non- sarcoidosis group. Pooled sensitivity and specificity of sIL-2R levels were 0.88 (95% CI: 0.75-0.95) and 0.87 (95% CI 0.73-0.94) respectively. Pooled negative predictive value and positive predictive value were 0.91 (95% CI 0.77-0.97) and 0.85 (95% CI 0.59-0.96) respectively with diagnostic accuracy of 0.86 (95% CI 0.71- 0.93). In addition to its utility as a marker of sarcoidosis disease activity, sIL-2R has high diagnostic accuracy. Despite the limitations of the heterogenous sarcoidosis population and different sIL-2R cutoffs, our results suggest that sIL-2R is an important biomarker that can be used to confirm sarcoidosis diagnosis in unconfirmed or unclear cases.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Serum Soluble Interleukin-2 Receptor (sIL-2R) levels are used clinically as a disease activity marker for systemic sarcoidosis. Studies have investigated the diagnostic role of serum soluble interleukin-2 receptor (sIL-2R) level for sarcoidosis relative to biopsy. We performed a systematic review and meta-analysis of studies evaluating the diagnostic utility of sIL-2R.
METHODS
METHODS
We carried out an electronic search in Medline, Embase, Google Scholar, and Cochrane databases using keyword and Medical Subject Heading (MeSH) terms: sarcoidosis and sIL-2R. Studies evaluating the sIL-2R levels as a diagnostic tool in clinically diagnosed or biopsy-proven sarcoidosis patients compared to control groups with non-sarcoidosis patients were included. Forest plots were constructed using a random effect model depicting pooled sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy.
RESULTS
RESULTS
We selected ten studies comprising 1477 patients, with 592 in the sarcoidosis group and 885 in the non- sarcoidosis group. Pooled sensitivity and specificity of sIL-2R levels were 0.88 (95% CI: 0.75-0.95) and 0.87 (95% CI 0.73-0.94) respectively. Pooled negative predictive value and positive predictive value were 0.91 (95% CI 0.77-0.97) and 0.85 (95% CI 0.59-0.96) respectively with diagnostic accuracy of 0.86 (95% CI 0.71- 0.93).
CONCLUSION
CONCLUSIONS
In addition to its utility as a marker of sarcoidosis disease activity, sIL-2R has high diagnostic accuracy. Despite the limitations of the heterogenous sarcoidosis population and different sIL-2R cutoffs, our results suggest that sIL-2R is an important biomarker that can be used to confirm sarcoidosis diagnosis in unconfirmed or unclear cases.
Identifiants
pubmed: 36975055
doi: 10.36141/svdld.v40i1.13499
pmc: PMC10099658
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2023005Références
Jpn J Ophthalmol. 2021 Mar;65(2):191-198
pubmed: 33420542
Eur Respir J. 2015 Jul;46(1):277-80
pubmed: 25745051
Front Immunol. 2020 Jul 14;11:1443
pubmed: 32760396
Ocul Immunol Inflamm. 2009 May-Jun;17(3):160-9
pubmed: 19585358
PLoS One. 2016 Jan 22;11(1):e0147258
pubmed: 26799486
Expert Rev Clin Immunol. 2019 Apr;15(4):391-405
pubmed: 30632406
JAMA Ophthalmol. 2017 Dec 1;135(12):1352-1358
pubmed: 29121154
Expert Rev Respir Med. 2020 Jul;14(7):749-756
pubmed: 32248706
Am J Respir Crit Care Med. 2020 Apr 15;201(8):e26-e51
pubmed: 32293205
Sarcoidosis Vasc Diffuse Lung Dis. 2017;34(2):122-129
pubmed: 32476833
Biomolecules. 2018 Aug 28;8(3):
pubmed: 30154391
PLoS One. 2019 Oct 17;14(10):e0223897
pubmed: 31622413
Int Immunopharmacol. 2015 Mar;25(1):174-9
pubmed: 25623898
Sarcoidosis Vasc Diffuse Lung Dis. 1999 Sep;16(2):149-73
pubmed: 10560120
Clin Chim Acta. 2020 Jan;500:155-162
pubmed: 31672631
J Med Biochem. 2016 Nov 02;35(4):390-400
pubmed: 28670191
Pol J Radiol. 2016 Sep 23;81:458-461
pubmed: 27733890
J Immunol. 2013 Jun 1;190(11):5446-53
pubmed: 23630356
Clin Ophthalmol. 2020 Aug 12;14:2311-2317
pubmed: 32848359